BioCentury
ARTICLE | Clinical News

Acadesine: Phase III started

May 18, 2009 7:00 AM UTC

Schering-Plough began the double-blind, placebo-controlled, international Phase III RED-CABG trial to evaluate 42 mg/kg IV acadesine given over 7 hours in 7,500 patients. Administration will begin wit...